@article{412fad9afad04f5bb105bacc1770a191,
title = "βTrCP- and Rsk1/2-Mediated Degradation of BimEL Inhibits Apoptosis",
abstract = "The BimEL tumor suppressor is a potent proapoptotic BH3-only protein. We found that, in response to survival signals, BimEL was rapidly phosphorylated on three serine residues in a conserved degron, facilitating binding and degradation via the F box protein βTrCP. Phosphorylation of the BimEL degron was executed by Rsk1/2 and promoted by the Erk1/2-mediated phosphorylation of BimEL on Ser69. Compared to wild-type BimEL, a BimEL phosphorylation mutant unable to bind βTrCP was stabilized and consequently potent at inducing apoptosis by the intrinsic mitochondrial pathway. Moreover, although non-small cell lung cancer (NSCLC) cells often become resistant to gefitinib (a clinically relevant tyrosine kinase inhibitor that induces apoptosis through BimEL), silencing of either βTrCP or Rsk1/2 resulted in BimEL-mediated apoptosis of both gefitinib-sensitive and gefitinib-insensitive NSCLC cells. Our findings reveal that βTrCP promotes cell survival in cooperation with the ERK-RSK pathway by targeting BimEL for degradation.",
keywords = "CELLCYCLE, PROTEINS",
author = "Elinor Dehan and Florian Bassermann and Daniele Guardavaccaro and Gaia Vasiliver-Shamis and Michael Cohen and Lowes, {Kym N.} and Michael Dustin and Huang, {David C.S.} and Jack Taunton and Michele Pagano",
note = "Funding Information: We thank M. McMahon, D. Ryoo, and J. Skaar for suggestions and for critically reading the manuscript; E. McIntush and Bethyl Laboratories for providing βTrCP1 (BL726b) antibody; and I. Aifantis, J. Blenis, P. Bouillet, S. Buonamici, T. Cardozo, C. Lee, S. Fuchs, K. Kinnally, S. Korsmeyer L. Liebes, J. Maller, W. Pao, S. Valvo, and H.G. Wang for reagents and/or suggestions. M.P. is grateful to T.M. Thor for continuous support. This work was supported by a Department of Defense fellowship to E.D.; an American Association for Cancer Research (AACR) fellowship to F.B.; a fellowship from the America Italian Cancer Foundation and from Provincia di Benevento to D.G.; grants from the National Institutes of Health to M.P. (R01-GM57587, R37-CA76584, and R21-CA125173), M.L.D. (R01-AI43542), and J.T. (GM071434); and an Australian National Health and Medical Research Council (NHMRC) Fellowship, an Australian NHMRC Program Grant, and a Leukemia and Lymphoma Society Specialized Center of Research (SCOR) grant (to D.C.S.H.). J.T. and M.P. are investigators with the Howard Hughes Medical Institute. ",
year = "2009",
month = jan,
day = "16",
doi = "10.1016/j.molcel.2008.12.020",
language = "English",
volume = "33",
pages = "109--116",
journal = "Molecular Cell",
issn = "1097-2765",
publisher = "Cell Press",
number = "1",
}